Royalty Pharma Plc Stock Filter Stocks by Fundamentals
| RPRX Stock | USD 39.84 0.30 0.76% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Royalty Pharma's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Royalty Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0522 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.70 % | ||||
| Current Valuation | 24.02 B | ||||
| Shares Outstanding | 427.25 M | ||||
| Shares Owned By Insiders | 8.84 % | ||||
| Shares Owned By Institutions | 81.60 % | ||||
| Number Of Shares Shorted | 24.03 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 2.63 X | ||||
| Price To Sales | 9.89 X | ||||
| Revenue | 2.26 B | ||||
| Gross Profit | 2.5 B | ||||
| EBITDA | 1.56 B | ||||
| Net Income | 1.33 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 7.61 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 14.95 X | ||||
| Cash Flow From Operations | 2.77 B | ||||
| Short Ratio | 6.62 X | ||||
| Earnings Per Share | 1.76 X | ||||
| Price To Earnings To Growth | 1.74 X | ||||
| Target Price | 45.98 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 23.23 B | ||||
| Total Asset | 18.22 B | ||||
| Retained Earnings | 2.85 B | ||||
| Working Capital | 548.52 M | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 18.22 B | ||||
| Last Dividend Paid | 0.87 |
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.